Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human mass balance study of AJM300 (carotegrast) with 14C labeling in healthy adult males
jRCT2080224740Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carotegrast in inflammatory bowel disease (IBD), sponsored by EA Pharma Co., Ltd. Primary endpoint: Mass balance (absorption, metabolism, excretion) of 14C-AJM300. Started Jun 2019; status: completed.
02
Drugs
carotegrast
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on jRCT2080224740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224740.